List of supplementary materials

Supplementary Table 1. Characteristics of data sources and sites contributing data

Country	Region	Site name	Data source(s)	Person-years calculation	Patient type
Scotland	National	Public Health Scotland	Hospital stay information is sourced from the Scottish Morbidity Record 01 (SMR01) acute inpatient and day case dataset. Population data is sourced from National Records Scotland (NRS) mid-year population estimates, for each respective year. Vaccine uptake data is sourced from the Turas Vaccine Management Tool.	Population-level vaccination uptake	Hospital inpatient
New Zealand	National	VADAR, School of Population Health, Waipapa Taumata Rau, University of Auckland	Te Whatu Ora Health New Zealand national administrative data collection. National Covid Immunisation Register (CIR).	Immunisation register with individual-level data	Hospital inpatient
France	National	Institut National de la Santé et de la Recherche Médicale (INSERM)	SNDS (Système National des Données de Santé). Administrative data from 3 linked databases at the individual level: hospital discharge; healthcare claims; COVID19 vaccination records.	Immunisation register with individual-level data	Hospital inpatient
Finland	National	Finnish Institute for Health and Welfare THL, Helsinki	Linked national registers, including the Care Register for Health Care (HILMO) and the Vaccination Register.	Immunisation register with individual-level data	All = Emergency department + Hospital inpatients
Denmark	National	Statens Serum Institut, Copenhagen	Danish nationwide registers (Central Person Register, National Vaccination Register, National Hospital Discharge Register)	Immunisation register with individual-level data	Hospital Inpatient / All = Emergency department + Hospital inpatient + Hospital outpatient
Canada	Ontario	ICES	Registered Persons Database; Discharge Abstracts Database (DAD); National Ambulatory Care Reporting System (NACRS); Provincial COVID-19 vaccination database COVaxON.	Immunisation register (COVaxON) with individual-level data	Emergency department / Hospital Inpatient / All = Emergency department + Hospital inpatient
Canada	British Columbia	British Columbia Provincial Health Services Authority	Discharge Abstracts Database (DAD)[1]; National Ambulatory Care Reporting System (NACRS)[2]; British Columbia Stats Population Estimates; British Columbia Provincial Immunization Registry[3].	Immunisation register with individual-level data	Emergency department / Hospital inpatient / All = Emergency department + Hospital inpatient

Australia	New South Wales (NSW)	National Centre for Immunisation Research and Surveillance	Admitted Patient Data Collection (APDC) (hospitalisations). Australian Immunisation Register (AIR) (vaccination records and coverage data for observed vs expected denominators). Australian Bureau of Statistics (ABS) (population data for background rates).	Population-level vaccination uptake	Hospital inpatient (public hospitals only)
Argentina *	Tierra del Fuego State	Clínica San Jorge, Hospital Regional Ushuaia, Hospital de Rio Grande	Institutional Database	Population-level vaccination uptake	All = Emergency department + Hospital inpatient + Hospital outpatient
Australia	Victoria	Murdoch Children's Research Institute	Victorian Emergency Minimum Dataset (VEMD). Victorian Admitted Episodes Dataset (VAED). Australian Immunisation Register (AIR).	Immunisation register with individual-level data	Emergency department / Hospital inpatient / All = Emergency department + Hospital inpatient

[1] British Columbia Ministry of Health [creator]. Discharge Abstract Database (Hospital Separations). British Columbia Ministry of Health [publisher]. Data Extract. MOH (2021). 2021.

[2] British Columbia Ministry of Health [creator]. National Ambulatory Care Reporting System. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2021). 2021.

[3] Provincial Health Services Authority [creator]. Provincial Public Health Information Systems [publisher]. (2021). 2021.

* Due to the lack of prior dose information, the Argentina data was not part of the global data (meta-analysis).

Supplementary Table 2. Study outcomes: Adverse event of special interest (AESI) according to the International Classification of Diseases 10th Revision (ICD-10) codes

Outcome category	**AESI**	**ICD-10 code(s)**	**Study code**
Neurological conditions	Guillain-Barré syndrome	G61.0	NE_GBS
	Transverse myelitis	G37.3	NE_TRM
	Facial (Bell's) palsy	G51.0	NE_BP
	Acute disseminated encephalomyelitis	G04.0	NE_ADEM
	Febrile seizures	R56.0	NE_FSZ
	Generalized seizures	G40.0-G40.9, G41.0, R56.8	NE_GSZ
Hematologic conditions	Thrombocytopenia	D69.5, D69.6	HM_THR
	Idiopathic thrombocytopenia	D69.3, D69.4	HM_ITP
	Pulmonary embolism	I26.0, I26.9	HM_PEM
	Cerebral venous sinus thrombosis	I63.6, I67.6	HM_CVST
	Splanchnic vein thrombosis	I81, I82.0, I82.3	HM_SVT
Cardiovascular conditions	Myocarditis	I40.1, I40.8, I40.9, I51.4	CV_MYO
	Pericarditis	I130.0, I130.8, I130.9	CV_PER

Supplementary Table 3. Ethical approvals

Site name	Approval or waiver	Name of institutional ethics committee
Hospital de Niños- FIPEC	Waiver	Epidemiología e Información de la Salud
Syndey Childrens Hospital Network	Approved	NSW Population and Health Services Research Ethics Committee
Murdoch Children's Research Institute	Approved	RCH Human Research Ethics Committee (HREC)
British Columbia Provincial Health Services Authority	Approved	The University of British Columbia Office of Research Services, Behavioural Research Ethics Board
ICES (Ontario)	Waiver	n/a
Statens Serum Institut- Denmark	Waiver	n/a
Finnish Institute for Health and Welfare	Waiver	n/a
INSERM	Waiver	n/a
Vaccine Datalink and Research Group	Approved	Auckland Health Research Ethics Committee
Public Health Scotland	Waiver	n/a

Supplementary Table 4. Population summary by site and all vaccine schedules

Characteristics		Argentina	Australia: NSW	Australia: Victoria	Canada: BC	Canada: Ontario	Denmark	Finland	France	New Zealand	Scotland
Study period		12/2020–08/2023	02/2021–12/2021	02/2021–06/2023	12/2020–05/2023	12/2020–03/2023	12/2020–02/2023	12/2020–06/2022	01/2021–12/2021	02/2021–09/2022	12/2020–05/2023
Vaccinated population	n	157,883	6,492,805	5,789,070	4,267,644	12,081,337	4,291,034	4,501,659	52,795,394	4,151,269	4,540,806
	Female (%)	78,374 (49.6)	3,289,381 (50.7)	2,925,886 (50.5)	2,183,666 (51.2)	6,192,991 (51.3)	2,179,415 (50.8)	2,324,067 (51.6)	27,216,365 (51.6)	2,100,071 (50.6)	2,346,694 (51.7)
	0-19 (%)	42,281 (26.8)	692,498 (10.7)	921,635 (15.9)	274,813 (6.4)	1,882,574 (15.6)	620,273 (14.5)	549,589 (12.2)	5,585,455 (10.6)	582,662 (14.0)	501,397 (11.0)
	20-39 (%)	58,567 (37.1)	2,125,624 (32.7)	1,858,706 (32.1)	1,386,513 (32.5)	3,421,403 (28.3)	1,100,566 (25.6)	1,159,303 (25.8)	14,517,426 (27.5)	1,321,332 (31.8)	1,218,142 (26.8)
	40-59 (%)	40,484 (25.6)	1,933,770 (29.8)	1,586,558 (27.4)	1,244,817 (29.2)	3,460,295 (28.6)	1,263,265 (29.4)	1,256,439 (27.9)	16,065,061 (30.4)	1,198,750 (28.9)	1,418,313 (31.2)
	60-79 (%)	15,167 (9.6)	1,433,446 (22.1)	1,139,623 (19.7)	1,103,315 (25.9)	2,706,343 (22.4)	1,063,018 (24.8)	1,234,825 (27.4)	12,997,416 (24.6)	865,928 (20.9)	1,142,053 (25.2)
	80+ (%)	1,384 (0.9)	307,467 (4.7)	282,548 (4.9)	258,186 (6.0)	610,722 (5.1)	243,912 (5.7)	301,503 (6.7)	3,630,036 (6.9)	182,597 (4.4)	260,901 (5.7)
BNT162b2	Dose 1		3,896,923 (60.0)	3,393,207 (58.6)	2,959,369 (69.3)	8,473,103 (70.1)	3,425,161 (79.8)	3,586,237 (79.7)	41,450,092 (78.5)	4,036,859 (97.2)	2,087,109 (46.0)
	Dose 2		3,837,153 (59.1)	3,313,758 (57.2)	2,778,036 (65.1)	7,382,893 (61.1)	3,480,685 (81.1)	3,594,661 (79.9)	38,876,671 (73.6)	3,990,353 (96.1)	1,967,726 (43.3)
	Dose 3		751,169 (11.6)	2,900,036 (50.1)	1,295,609 (30.4)	4,377,649 (36.2)	2,811,507 (65.5)	2,167,380 (48.1)	16,121,693 (30.5)	2,730,880 (65.8)	2,557,434 (56.3)
	Dose 4			969,442 (16.7)	259,228 (6.1)	1,469,297 (12.2)	1,609,558 (37.5)		54,905 (0.1)	595,269 (14.3)	358,410 (7.9)
	Dose 5			63,184 (1.1)		8,524 (0.1)			4,819 (<0.1)	5,043 (0.1)	16,159 (0.4)
	Dose 6			14,595 (0.3)					98 (<0.1)	49 (<0.1)	164 (<0.1)
	Dose 7			5,492 (0.1)						8 (<0.1)	54 (<0.1)
	Dose 8									1–4 (<0.1)	7 (<0.1)
	Dose 9										
mRNA-1273	Dose 1	2,850 (1.8)	134,960 (2.1)	199,865 (3.5)	940,656 (22.0)	2,100,866 (17.4)	507,031 (11.8)	554,076 (12.3)	5,853,595 (11.1)	3,255 (0.1)	205,528 (4.5)
	Dose 2	13,046 (8.3)	126,291 (1.9)	190,271 (3.3)	1,196,017 (28.0)	3,589,447 (29.7)	578,985 (13.5)	532,153 (11.8)	5,880,520 (11.1)	3,211 (0.1)	183,966 (4.1)
	Dose 3	45,712 (29.0)	117,804 (1.8)	617,724 (10.7)	1,482,817 (34.7)	2,965,640 (24.5)	61,548 (1.4)	812,002 (18.0)	4,676,771 (8.9)	2,184 (0.1)	970,917 (21.4)
	Dose 4			257,557 (4.4)	380,862 (8.9)	723,201 (6.0)	56,850 (1.3)		14,245 (<0.1)	134 (<0.1)	195,885 (4.3)
	Dose 5			19,573 (0.3)		4,391 (<0.1)			631 (<0.1)	8 (<0.1)	14,539 (0.3)
	Dose 6			3,449 (0.1)					18 (<0.1)	1–4 (<0.1)	54 (<0.1)
	Dose 7			1,404 (<0.1)							1–4 (<0.1)
	Dose 8										
ChAdOx1	Dose 1	37,721 (23.9)	2,460,922 (37.9)	1,868,764 (32.3)	308,867 (7.2)	856,603 (7.1)	133,181 (3.1)	360,196 (8.0)	4,398,411 (8.3)	17,087 (0.4)	2,139,669 (47.1)
	Dose 2	36,164 (22.9)	2,433,046 (37.5)	1,835,469 (31.7)	132,111 (3.1)	221,118 (1.8)	1,780 (<0.1)	191,120 (4.2)	3,424,058 (6.5)	14,560 (0.4)	2,093,121 (46.1)
	Dose 3	28,255 (17.9)	7,483 (0.1)	57,841 (1)	1,757 (<0.1)		46 (<0.1)	306 (<0.1)	7,368 (<0.1)	2,058 (<0.1)	9,551 (0.2)
	Dose 4			13,693 (0.2)	76 (<0.1)				90 (<0.1)	212 (<0.1)	695 (<0.1)
	Dose 5			1,138 (<0.1)					1–4 (<0.1)	6 (<0.1)	76 (<0.1)
BIBNT	Dose 1	14,399 (9.1)		6,949 (0.1)		9,128 (0.1)				1–4 (<0.1)	241 (<0.1)
	Dose 2	13,605 (8.6)		2,191 (<0.1)		3,043 (<0.1)					
	Dose 3	40,661 (25.8)		20,135 (0.3)		76,400 (0.6)				1–4 (<0.1)	17,220 (0.4)

	Dose 4			122,581 (2.1)		796,486 (6.6)					712,553 (15.7)
	Dose 5			403,904 (7)		803,041 (6.6)					213,093 (4.7)
	Dose 6			15,854 (0.3)		11,286 (0.1)					223,060 (4.9)
	Dose 7			2,067 (<0.1)							8,979 (0.2)
	Dose 8										69 (<0.1)
	Dose 9										16 (<0.1)
BIMODO	Dose 1			3,191 (0.1)		4,172 (<0.1)				6 (<0.1)	219 (<0.1)
	Dose 2			1,138 (<0.1)		1,634 (<0.1)				8 (<0.1)	
	Dose 3			11,247 (0.2)		34,180 (0.3)				24 (<0.1)	14,282 (0.3)
	Dose 4			106,049 (1.8)		579,059 (4.8)				18 (<0.1)	759,724 (16.7)
	Dose 5			143,872 (2.5)		589,391 (4.9)				1–4 (<0.1)	329,576 (7.3)
	Dose 6			6,281 (0.1)		2,817 (<0.1)					155,425 (3.4)
	Dose 7			1,028 (<0.1)							7,093 (0.2)
	Dose 8										35 (<0.1)
	Dose 9										5 (<0.1)
PBNT	Dose 1	121 (0.1)		305,954 (5.3)	31 (<0.1)	637,465 (5.3)	183,276 (4.3)		19,213 (<0.1)	85,525 (2.1)	107,720 (2.4)
	Dose 2	53 (<0.1)		242,173 (4.2)	8 (<0.1)	489,857 (4.1)	152,250 (3.5)		215 (<0.1)	54,385 (1.3)	70,257 (1.5)
	Dose 3	3,259 (2.1)		2,887 (<0.1)	9 (<0.1)	78,564 (0.7)	1–4 (<0.1)		451 (<0.1)	56 (<0.1)	2,422 (0.1)
	Dose 4			540 (<0.1)		2,251 (<0.1)	1–4 (<0.1)		1–4 (<0.1)	1–4 (<0.1)	98 (<0.1)
	Dose 5			22 (<0.1)							9 (<0.1)
	Dose 6			7 (<0.1)							1–4 (<0.1)
JJJ	Dose 1				12,542 (0.3)		42,385 (1.0)	151 (<0.1)	1,074,083 (2.0)	1,225 (<0.1)	
	Dose 2				565 (<0.1)		1–4 (<0.1)	73 (<0.1)	5,415 (<0.1)	28 (<0.1)	
	Dose 3				215 (<0.1)			127 (<0.1)	656 (<0.1)	24 (<0.1)	
	Dose 4				12 (<0.1)				1–4 (<0.1)		
	Dose 5								1–4 (<0.1)		
	Dose 7									1–4 (<0.1)	
HMOD	Dose 1			719 (<0.1)	19,958 (0.5)						
	Dose 2			470 (<0.1)	75 (<0.1)						
	Dose 3			15 (<0.1)	5 (<0.1)		378,094 (8.8)				
	Dose 4			1–4 (<0.1)	7 (<0.1)		1,050 (<0.1)				
BIBP	Dose 1	57,762 (36.6)			9,960 (0.2)					1,687 (<0.1)	
	Dose 2	53,248 (33.7)			8,687 (0.2)					1,558 (<0.1)	
	Dose 3	235 (0.1)			1,186 (<0.1)					197 (<0.1)	
	Dose 4				25 (<0.1)					5 (<0.1)	

VGM	Dose 1	44,682 (28.3)								531 (<0.1)	
	Dose 2	30,728 (19.5)								509 (<0.1)	
	Dose 3	8,003 (5.1)								5 (<0.1)	
	Dose 4									1–4 (<0.1)	
NVX	Dose 1			10,421 (0.2)	2,121 (<0.1)			999 (<0.1)		2,345 (0.1)	320 (<0.1)
	Dose 2			9,340 (0.2)	1,980 (<0.1)			758 (<0.1)		2,168 (0.1)	265 (<0.1)
	Dose 3			14,357 (0.2)	579 (<0.1)			335 (<0.1)		746 (<0.1)	12 (<0.1)
	Dose 4			14,214 (0.2)	687 (<0.1)					939 (<0.1)	516 (<0.1)
	Dose 5			2,958 (0.1)						30 (<0.1)	176 (<0.1)
	Dose 6			322 (<0.1)							137 (<0.1)
	Dose 7			116 (<0.1)							15 (<0.1)
SINO	Dose 1				13,199 (0.3)					2,244 (0.1)	
	Dose 2				12,595 (0.3)					2,135 (0.1)	
	Dose 3				1,154 (<0.1)					248 (<0.1)	
	Dose 4				14 (<0.1)					5 (<0.1)	
	Dose 5									1–4 (<0.1)	
	Dose 6									1–4 (<0.1)	
ADN	Dose 1	348 (0.2)			243 (<0.1)					39 (<0.1)	
	Dose 2	125 (0.1)			20 (<0.1)					11 (<0.1)	
	Dose 3	3,143 (2.0)			6 (<0.1)					1–43 (<0.1)	
BBV	Dose 1				696 (<0.1)					152 (<0.1)	
	Dose 2				611 (<0.1)					145 (<0.1)	
	Dose 3				47 (<0.1)					8 (<0.1)	
	Dose 4				1–4 (<0.1)						
WIBP	Dose 1				1–4 (<0.1)					290 (<0.1)	
	Dose 2				1–4 (<0.1)					262 (<0.1)	
	Dose 3									65 (<0.1)	
	Dose 4									1–4 (<0.1)	
LGM	Dose 1									17 (<0.1)	
	Dose 2									1–4 (<0.1)	
	Dose 3									5 (<0.1)	
MVC	Dose 1									6 (<0.1)	
	Dose 2									5 (<0.1)	
	Dose 3									1–4 (<0.1)	
	Dose 3									1–4 (<0.1)	

Vaccine abbreviations:

Code	Vaccine brand
BIBNT	Comirnaty or Riltozinameran or Pfizer/BioNTech COVID-19 Vaccine Bivalent [Pfizer/BioNTech]
BIMODO	Spikevax bivalent Original/Omicron [Moderna]
PBNT	Comirnaty or Tozinameran Paediatric [Pfizer/BioNTech or Fosun-BioNTech]
JJJ	Janssen [Janssen/Johnson & Johnson]
HMOD	Elasomeran or Spikevax or TAK-919 Half Dose [Moderna or Takeda]
BIBP	Covilo or SARS-CoV-2 Vaccine (Vero Cell) [Sinopharm (Beijing)]
VGM	Sputnik V [Gamaleya Research Institute]
NVX	Covovax or Nuvaxoid [Novavax or Serum Institute of India]
SINO	CoronaVac or Sinovac [Sinovac Biotech]
ADN	Convidecia or Convidence [CanSino]
BBV	Covaxin [Bharat Biotech]
WIBP	Inactivated (Vero cell) [Sinopharm (Wuhan)]
LGM	Sputnik Light or Gam-COVID-Vac [Gamaleya Research Institute]
MVC	MVC-COV1901 [Medigen]

Supplementary Table 5. Percentage of vaccinations included in aggregated and homologous analyses by site

Analysis	Argentina	Australia: NSW	Australia: Victoria	Canada: BC	Canada: Ontario	Denmark	Finland	France	New Zealand	Scotland	Overall
Aggregated	37.7	100	90.9	99.3	88.6	94.4	100	99.1	98.6	82.8	95.8
Homologous	37.7	96.6	90.9	80.7	70.8	90.6	88.7	91.2	98.4	64.7	86.6

Supplementary Table 6. Guillain-Barré syndrome; Aggregated OE Ratios by last dose and site, period 0–42 days

		Overall		Australia:NSW		Australia:Victoria		Canada:BC		Canada:Ontario		Denmark		Finland		France		New Zealand		Scotland	
Dose	Vaccine	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI
1	ChAdOx1	2.49	(2.15,2.87)	2.53	(1.73,3.57)	3.13	(2.24,4.24)	-		6.83	(3.98,10.94)	-		-		1.61	(1.21,2.09)			3.62	(2.56,4.97)
	BNT162b2	0.90	(0.79,1.03)	0.95	(0.45,1.74)	1.47	(0.81,2.47)	-		0.60	(0.30,1.07)	0.56	(0.21,1.23)	0.40	(0.13,0.93)	1.03	(0.87,1.20)	0.98	(0.42,1.93)	-	
	mRNA-1273	0.95	(0.65,1.34)	-		-		-		1.31	(0.48,2.85)	0		-		1.02	(0.65,1.53)			0	
2	ChAdOx1	0.73	(0.54,0.96)	0.88	(0.44,1.57)	0.61	(0.26,1.20)	-		0				-		0.62	(0.37,0.98)			0.96	(0.46,1.77)
	BNT162b2	0.69	(0.60,0.79)	-		0.66	(0.30,1.26)	-		0.65	(0.33,1.17)	0.80	(0.41,1.40)	0.69	(0.32,1.31)	0.72	(0.61,0.85)	0.53	(0.20,1.16)	0.93	(0.34,2.02)
	mRNA-1273	0.84	(0.60,1.15)	0		-		-		0.70	(0.26,1.52)	-		-		0.87	(0.57,1.28)			0	
3	ChAdOx1	3.99	(0.48,14.41)																		
	BNT162b2	0.66	(0.54,0.79)	-		0.64	(0.32,1.14)	-		0.44	(0.14,1.04)	1.04	(0.57,1.74)	0.55	(0.18,1.29)	0.55	(0.40,0.73)	0.99	(0.45,1.88)	1.26	(0.70,2.07)
	mRNA-1273	0.68	(0.45,1.00)	0		-		-		0.86	(0.34,1.77)			-		0.50	(0.20,1.04)			-	
4	BNT162b2	0.87	(0.56,1.29)			-		-		1.18	(0.43,2.57)	0.93	(0.43,1.77)					-		-	
	mRNA-1273	0.88	(0.32,1.92)			-		-		-										-	

Vaccines: Pfizer/BioNTech (BNT162b2), Moderna (mRNA-1273), and Oxford/Astra Zeneca/Serum Institute of India (ChAdOx1)

Supplementary Table 7. Acute disseminated encephalomyelitis; Aggregated OE Ratios by last dose and site, period 0–42 days

		Overall		Australia:NSW		Australia:Victoria		Canada:BC		Canada:Ontario		Denmark		Finland		France		New Zealand		Scotland	
Dose	Vaccine	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI
1	ChAdOx1	2.23	(1.15,3.90)	5.30	(1.72,12.36)	-		0		0		0		-		-				-	
	BNT162b2	1.28	(0.77,2.00)	-		-		0		-		-		0		1.04	(0.48,1.98)	-		-	
	mRNA-1273	3.78	(1.52,7.78)	-		-		0		0		0		0		4.92	(1.80,10.70)			0	
2	ChAdOx1	1.63	(0.70,3.21)	-		-		0		0				0		-				0	
	BNT162b2	0.54	(0.23,1.06)	-		-		0		0		0		0		0.47	(0.15,1.10)	-		0	
	mRNA-1273	1.21	(0.25,3.55)	0		-		-		-		0		0		-				0	
3	ChAdOx1	0																			
	BNT162b2	0.82	(0.30,1.79)	0		-		-		0		-		-		-		0		0	
	mRNA-1273	0.64	(0.02,3.58)	0		-		0		0				-		0				0	
4	BNT162b2	2.26	(0.06,12.62)			-		0		-		0						0		0	
	mRNA-1273	0				-		0		0										0	

Vaccines: Pfizer/BioNTech (BNT162b2), Moderna (mRNA-1273), and Oxford/Astra Zeneca/Serum Institute of India (ChAdOx1)

Supplementary Table 8. Cerebral venous sinus thrombosis; Aggregated OE Ratios by last dose and site, period 0–42 days

		Overall		Australia:NSW		Australia:Victoria		Canada:BC		Canada:Ontario		Denmark		Finland		France		New Zealand		Scotland	
Dose	Vaccine	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI
1	ChAdOx1	3.23	(2.51,4.09)	11.07	(5.72,19.33)	2.47	(1.28,4.32)	0		-		11.32	(3.67,26.41)	4.10	(1.50,8.92)	2.32	(1.54,3.36)			-	
	BNT162b2	1.49	(1.26,1.75)	0		1.30	(0.48,2.84)	0		1.11	(0.41,2.42)	1.21	(0.55,2.29)	1.15	(0.61,1.96)	1.64	(1.35,1.97)	-		-	
	mRNA-1273	1.48	(0.92,2.23)	0		-		-		-		-		-		1.20	(0.62,2.09)			0	
2	ChAdOx1	1.15	(0.70,1.77)	5.59	(2.05,12.17)	-		0		0				-		0.72	(0.29,1.48)			-	
	BNT162b2	1.25	(1.06,1.46)	-		0.91	(0.33,1.99)	-		1.21	(0.45,2.64)	1.70	(1.01,2.69)	1.03	(0.53,1.79)	1.25	(1.03,1.52)	-		-	
	mRNA-1273	1.43	(0.95,2.06)	0		-		-		2.47	(0.91,5.38)	-		-		1.33	(0.78,2.14)			0	
3	ChAdOx1	0																			
	BNT162b2	1.14	(0.89,1.44)	0		1.67	(0.87,2.92)	0		1.89	(0.69,4.11)	1.21	(0.60,2.17)	1.22	(0.59,2.25)	0.99	(0.67,1.41)	0		-	
	mRNA-1273	0.94	(0.49,1.65)	0		-		0		-				0		1.13	(0.42,2.46)			-	
4	BNT162b2	0.99	(0.47,1.81)			-		0		-		1.08	(0.40,2.35)					0		-	
	mRNA-1273	0				-		0		0										0	

Vaccines: Pfizer/BioNTech (BNT162b2), Moderna (mRNA-1273), and Oxford/Astra Zeneca/Serum Institute of India (ChAdOx1)

Supplementary Table 9. Myocarditis; Aggregated OE Ratios by last dose and site, period 0–42 days

		Overall		Australia:NSW		Australia:Victoria		Canada:BC		Canada:Ontario		Denmark		Finland		France		New Zealand		Scotland	
Dose	Vaccine	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI
1	ChAdOx1	1.36	(1.08,1.68)	2.01	(1.21,3.13)	2.50	(1.60,3.72)	0		-		0		-		1.01	(0.68,1.44)			-	
	BNT162b2	2.78	(2.61,2.95)	3.13	(2.30,4.17)	5.69	(4.53,7.07)	0.85	(0.44,1.49)	7.23	(6.08,8.53)	1.79	(1.16,2.65)	1.27	(0.97,1.64)	2.68	(2.47,2.91)	3.60	(2.50,5.03)	-	
	mRNA-1273	3.48	(3.00,4.01)	0		11.08	(5.31,20.38)	-		6.63	(4.57,9.32)	3.06	(1.23,6.30)	0.78	(0.29,1.70)	3.91	(3.26,4.65)			-	
2	ChAdOx1	1.31	(1.01,1.68)	1.60	(0.90,2.64)	1.57	(0.88,2.58)	0		0				-		1.15	(0.76,1.68)			1.63	(0.66,3.36)
	BNT162b2	2.86	(2.70,3.03)	6.37	(5.15,7.79)	9.26	(7.99,10.68)	3.46	(2.54,4.60)	7.05	(5.87,8.41)	2.63	(1.95,3.47)	1.81	(1.45,2.23)	1.96	(1.80,2.14)	5.67	(4.43,7.15)	2.60	(1.30,4.65)
	mRNA-1273	6.10	(5.52,6.72)	13.41	(4.92,29.20)	23.71	(15.62,34.50)	6.33	(4.48,8.69)	13.10	(10.85,15.68)	7.28	(4.71,10.75)	5.56	(3.91,7.66)	3.91	(3.33,4.58)			-	
3	ChAdOx1	0																			
	BNT162b2	2.09	(1.88,2.32)	1.80	(0.58,4.20)	4.23	(3.31,5.33)	3.88	(2.49,5.77)	3.09	(2.12,4.37)	2.04	(1.39,2.90)	1.64	(1.17,2.23)	1.35	(1.10,1.63)	3.48	(2.38,4.91)	1.89	(0.91,3.48)
	mRNA-1273	2.01	(1.60,2.49)	-		5.71	(3.27,9.28)	1.91	(1.02,3.27)	3.59	(2.32,5.30)			-		1.51	(0.94,2.31)			-	
4	BNT162b2	2.06	(1.47,2.80)			2.20	(1.06,4.05)	-		2.44	(1.05,4.80)	1.76	(0.96,2.96)					-		-	
	mRNA-1273	2.91	(1.45,5.21)			-		3.16	(1.03,7.38)	-										-	

Vaccines: Pfizer/BioNTech (BNT162b2), Moderna (mRNA-1273), and Oxford/Astra Zeneca/Serum Institute of India (ChAdOx1)

Supplementary Table 10. Pericarditis; Aggregated OE Ratios by last dose and site, period 0–42 days

		Overall		Australia:NSW		Australia:Victoria		Canada:BC		Canada:Ontario		Denmark		Finland		France		New Zealand		Scotland	
Dose	Vaccine	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI
1	ChAdOx1	1.29	(1.15,1.44)	1.01	(0.69,1.42)	3.43	(2.87,4.07)	0		1.80	(1.07,2.85)	2.41	(0.78,5.62)	-		0.72	(0.58,0.87)			1.44	(0.94,2.11)
	BNT162b2	1.54	(1.47,1.62)	1.37	(0.99,1.85)	6.78	(6.15,7.47)	0.27	(0.13,0.50)	1.83	(1.54,2.15)	1.57	(1.24,1.96)	0.91	(0.53,1.45)	1.15	(1.07,1.23)	1.55	(0.92,2.45)	1.12	(0.60,1.92)
	mRNA-1273	1.74	(1.54,1.97)	-		10.65	(7.61,14.51)	-		2.33	(1.71,3.10)	1.76	(0.96,2.96)	-		1.49	(1.26,1.74)			-	
2	ChAdOx1	1.27	(1.12,1.43)	1.11	(0.77,1.54)	3.24	(2.70,3.86)	-		-				-		0.71	(0.56,0.88)			0.96	(0.56,1.53)
	BNT162b2	1.38	(1.32,1.45)	2.11	(1.63,2.70)	5.28	(4.80,5.78)	0.92	(0.63,1.30)	1.88	(1.58,2.22)	1.43	(1.16,1.75)	1.28	(0.83,1.89)	0.94	(0.88,1.01)	1.77	(1.18,2.56)	1.50	(0.87,2.40)
	mRNA-1273	1.67	(1.50,1.85)	-		7.62	(5.34,10.55)	1.44	(0.91,2.19)	2.77	(2.26,3.35)	2.53	(1.70,3.61)	3.31	(1.51,6.28)	1.06	(0.89,1.25)			-	
3	ChAdOx1	6.91	(3.45,12.36)																		
	BNT162b2	1.19	(1.10,1.28)	1.03	(0.47,1.96)	3.29	(2.88,3.74)	1.54	(1.00,2.27)	1.46	(1.14,1.84)	1.50	(1.20,1.85)	1.74	(1.12,2.59)	0.67	(0.59,0.76)	0.97	(0.50,1.70)	0.75	(0.42,1.24)
	mRNA-1273	1.39	(1.20,1.59)	-		4.69	(3.68,5.90)	1.60	(1.10,2.26)	1.25	(0.91,1.69)			-		0.61	(0.42,0.84)			0.72	(0.23,1.68)
4	BNT162b2	1.55	(1.30,1.83)			3.00	(2.28,3.89)	2.35	(1.13,4.33)	0.98	(0.61,1.50)	1.09	(0.77,1.50)					-		-	
	mRNA-1273	2.64	(2.05,3.35)			5.67	(3.82,8.09)	2.47	(1.38,4.07)	1.59	(0.93,2.55)									-	

Vaccines: Pfizer/BioNTech (BNT162b2), Moderna (mRNA-1273), and Oxford/Astra Zeneca/Serum Institute of India (ChAdOx1)

Thresholds for statistical indications of potential signals:

Red: LBCI* >1.5, statistically significant safety signal

Yellow: LBCI* >1 and ≤1.5, statistically significant

Green: LBCI* ≤1.0, not statistically significant

*LBCI: Lower bound of confidence interval

Conditions applied to the analysis of aggregated OE ratios by site:

- PYRS ≥10000
- OE ratios and 95% CI were suppressed (-) if fewer than five events were observed

Supplementary Tables 11-13: Supplemental analysis including all vaccines from GVDN sites

Supplementary Table 11: All aggregated OE Ratios by last dose, neurological conditions, period 0–42 days, PYRS≥1000, no censoring on observed counts

		GBS		TRM		BP		ADEM		FSZ		GSZ	
Dose	Vaccine	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI
1	AZD	2.49	(2.15,2.87)	1.91	(1.22,2.84)	0.98	(0.88,1.08)	2.23	(1.15,3.90)	0.93	(0.55,1.46)	0.86	(0.83,0.90)
	BNT	0.90	(0.79,1.03)	0.74	(0.53,1.02)	1.05	(1.00,1.11)	1.28	(0.77,2.00)	0.73	(0.53,0.97)	0.92	(0.91,0.94)
	MOD	0.95	(0.65,1.34)	1.50	(0.77,2.62)	1.25	(1.11,1.39)	3.78	(1.52,7.78)	1.36	(1.02,1.77)	1.15	(1.10,1.20)
	BIBNT	0		0		1.42	(0.04,7.89)	0		0		0.89	(0.11,3.23)
	NVX	0		0		0		0		0		2.70	(0.33,9.77)
	PBNT	0.79	(0.02,4.38)	1.96	(0.05,10.93)	0.91	(0.49,1.56)	1.40	(0.04,7.81)	1.01	(0.72,1.37)	0.81	(0.71,0.93)
	BIBP	0		0		0.88	(0.18,2.56)	0		0		2.15	(1.03,3.95)
	VGM	0		0		0.91	(0.25,2.34)	0		0		5.50	(2.74,9.84)
	JJJ	1.60	(0.85,2.73)	2.35	(0.28,8.49)	1.00	(0.71,1.36)	0		0		0.97	(0.87,1.08)
	SINO	0		0		0		0		0		0	
	HMOD	0		0		0		0		0.70	(0.19,1.80)	0.43	(0.09,1.26)
2	AZD	0.73	(0.54,0.96)	0.58	(0.21,1.26)	0.95	(0.85,1.06)	1.63	(0.70,3.21)	0.45	(0.20,0.89)	0.77	(0.74,0.81)
	BNT	0.69	(0.60,0.79)	0.84	(0.62,1.11)	0.93	(0.88,0.97)	0.54	(0.23,1.06)	0.58	(0.42,0.79)	0.81	(0.80,0.83)
	MOD	0.84	(0.60,1.15)	1.27	(0.69,2.12)	1.02	(0.91,1.13)	1.21	(0.25,3.55)	1.44	(1.04,1.95)	0.97	(0.93,1.01)
	BIBNT	0		0		0		0		0		3.29	(0.90,8.43)
	NVX	62.83	(1.59,350.05)	0		0		0		0		1.25	(0.03,6.99)
	PBNT	0		0		0.11	(0.00,0.61)	0		0.82	(0.53,1.21)	0.81	(0.69,0.93)
	BIBP	0		0		0.90	(0.18,2.62)	0		3.11	(0.64,9.08)	1.76	(0.76,3.46)
	VGM	0		0		0.33	(0.01,1.85)	0		0		3.43	(1.11,8.00)
	SINO	0		0		0		0		0		0	
3	AZD	3.99	(0.48,14.41)	0		0.75	(0.20,1.92)	0		2.88	(0.07,16.04)	0.71	(0.44,1.10)
	BNT	0.66	(0.54,0.79)	1.02	(0.68,1.46)	0.81	(0.76,0.87)	0.82	(0.30,1.79)	0.97	(0.69,1.33)	0.80	(0.78,0.82)
	MOD	0.68	(0.45,1.00)	0.92	(0.40,1.81)	0.83	(0.74,0.94)	0.64	(0.02,3.58)	0.58	(0.19,1.36)	0.69	(0.66,0.73)
	BIBNT	4.19	(0.11,23.37)	0		0.58	(0.16,1.48)	0		0		1.24	(0.83,1.77)
	BIMODO	0		0		0.65	(0.02,3.63)	0		0		1.79	(1.07,2.79)
	NVX	0		0		0		0		0		3.87	(0.10,21.57)
	PBNT	0		0		1.07	(0.03,5.95)	0		0.47	(0.01,2.59)	1.84	(1.20,2.70)
	HMOD	0		2.66	(0.32,9.62)	1.10	(0.57,1.93)	0		0		0.99	(0.84,1.16)
4	AZD	0		0		6.58	(1.36,19.23)	0		0		1.50	(0.55,3.27)
	BNT	0.87	(0.56,1.29)	1.05	(0.39,2.29)	1.14	(0.99,1.29)	2.26	(0.06,12.62)	0.99	(0.43,1.94)	1.09	(1.04,1.14)
	MOD	0.88	(0.32,1.92)	1.25	(0.15,4.50)	1.08	(0.83,1.38)	0		0.85	(0.02,4.75)	1.00	(0.91,1.10)
	BIBNT	0.87	(0.28,2.04)	1.21	(0.15,4.36)	1.01	(0.74,1.34)	0		1.65	(0.04,9.20)	0.83	(0.74,0.93)
	BIMODO	1.28	(0.52,2.65)	0		0.89	(0.62,1.23)	0		0		0.76	(0.67,0.86)
	NVX	0		0		0		0		0		0.82	(0.10,2.97)
5	BNT	0		0		2.38	(0.65,6.10)	0		0		0.72	(0.44,1.11)
	MOD	12.31	(1.49,44.46)	0		1.40	(0.04,7.80)	0		0		0.82	(0.33,1.69)
	BIBNT	0.46	(0.09,1.34)	0		0.90	(0.67,1.17)	1.78	(0.04,9.90)	0		0.66	(0.58,0.74)
	BIMODO	1.02	(0.33,2.37)	2.17	(0.26,7.84)	1.03	(0.74,1.39)	0		1.81	(0.22,6.56)	0.77	(0.68,0.87)
6	BNT	0		0		0		0		0		15.65	(3.23,45.74)
	BIBNT	0.51	(0.01,2.86)	6.58	(0.17,36.69)	0.14	(0.00,0.79)	0		0		0.50	(0.38,0.66)
	BIMODO	0		0		0.43	(0.05,1.56)	0		0		0.37	(0.24,0.54)
7	BIBNT	0		0		4.99	(0.13,27.83)	0		0		0.93	(0.19,2.71)

AESI: GBS= Guillain-Barré syndrome, TRM= Transverse myelitis, BP= Facial (Bell's) palsy, ADEM= Acute disseminated encephalomyelitis, FSZ= Febrile seizures, GSZ= Generalised seizures

Supplementary Table 12: All aggregated OE Ratios by last dose, haematologic conditions, period 0–42 days, PYRS≥1000, no censoring on observed counts

		THR		ITP		PEM		CVST		SVT	
Dose	Vaccine	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI	OE_Ratio	CI
1	AZD	1.07	(1.03,1.12)	1.40	(1.24,1.58)	1.20	(1.16,1.24)	3.23	(2.51,4.09)	1.02	(0.89,1.16)
	BNT	1.11	(1.08,1.14)	1.08	(1.01,1.16)	1.29	(1.26,1.32)	1.49	(1.26,1.75)	1.25	(1.17,1.34)
	MOD	1.33	(1.25,1.42)	1.13	(0.93,1.37)	1.33	(1.26,1.40)	1.48	(0.92,2.23)	1.23	(1.03,1.47)
	BIBNT	0		0		2.58	(0.31,9.30)	0		0	
	NVX	0		0		3.01	(0.82,7.71)	0		34.57	(0.88,192.63)
	PBNT	0.55	(0.28,0.99)	0.77	(0.33,1.51)	0		0		1.22	(0.03,6.81)
	BIBP	0		0		0		0		0	
	VGM	0		0		0		0		0	
	JJJ	0.95	(0.82,1.09)	0.64	(0.33,1.11)	1.07	(0.94,1.21)	1.01	(0.21,2.96)	0.99	(0.67,1.40)
	SINO	0		0		0		0		0	
	HMOD	0		0		0		0		0	
2	AZD	0.96	(0.91,1.01)	1.02	(0.88,1.18)	0.96	(0.92,1.00)	1.15	(0.70,1.77)	0.95	(0.82,1.10)
	BNT	0.92	(0.89,0.94)	0.93	(0.86,1.00)	0.99	(0.97,1.01)	1.25	(1.06,1.46)	1.03	(0.96,1.10)
	MOD	0.98	(0.92,1.04)	0.80	(0.65,0.97)	1.05	(0.99,1.10)	1.43	(0.95,2.06)	1.17	(1.01,1.36)
	BIBNT	0		0		3.33	(0.08,18.57)	0		0	
	NVX	3.28	(0.68,9.59)	0		2.16	(0.05,12.04)	0		0	
	PBNT	0.29	(0.06,0.84)	0.57	(0.16,1.47)	0		3.55	(0.09,19.80)	4.03	(0.49,14.57)
	BIBP	0		0		0		0		0	
	VGM	0		0		0		0		0	
	SINO	0		0		0		0		0	
3	AZD	1.95	(1.29,2.84)	3.65	(0.75,10.67)	1.88	(1.32,2.58)	0		3.59	(0.43,12.96)
	BNT	0.78	(0.75,0.81)	0.85	(0.77,0.93)	0.96	(0.93,0.98)	1.14	(0.89,1.44)	0.90	(0.82,0.99)
	MOD	0.73	(0.67,0.79)	0.72	(0.57,0.91)	0.97	(0.92,1.02)	0.94	(0.49,1.65)	0.94	(0.77,1.13)
	BIBNT	1.26	(0.51,2.60)	0.87	(0.02,4.85)	2.20	(1.30,3.48)	15.01	(0.38,83.62)	1.63	(0.04,9.09)
	BIMODO	1.30	(0.35,3.33)	2.44	(0.06,13.61)	1.07	(0.39,2.34)	0		2.34	(0.06,13.02)
	NVX	1.51	(0.04,8.43)	0		0		546.57	(13.84,3045.28	0	
	PBNT	0.89	(0.02,4.98)	1.92	(0.05,10.67)	0		0		0	
	HMOD	0.80	(0.26,1.86)	1.35	(0.67,2.41)	0.80	(0.59,1.05)	0		0.87	(0.18,2.54)
4	AZD	2.72	(1.00,5.92)	0		3.33	(1.60,6.12)	0		6.90	(0.17,38.45)
	BNT	1.04	(0.95,1.13)	1.18	(0.99,1.41)	0.99	(0.94,1.04)	0.99	(0.47,1.81)	1.30	(1.06,1.59)
	MOD	1.08	(0.93,1.24)	0.96	(0.59,1.47)	1.03	(0.93,1.13)	0		1.53	(1.05,2.16)
	BIBNT	0.86	(0.68,1.07)	0.81	(0.43,1.38)	0.92	(0.80,1.06)	5.16	(1.41,13.22)	0.67	(0.32,1.23)
	BIMODO	0.69	(0.52,0.90)	1.10	(0.63,1.78)	0.99	(0.85,1.13)	1.53	(0.04,8.54)	1.07	(0.60,1.77)
	NVX	1.33	(0.16,4.81)	0		3.25	(1.19,7.07)	0		0	
5	BNT	2.05	(1.36,2.97)	4.57	(1.68,9.94)	1.63	(1.14,2.26)	0		2.67	(0.55,7.79)
	MOD	2.45	(1.22,4.39)	1.91	(0.05,10.66)	2.72	(1.58,4.35)	0		0	
	BIBNT	0.73	(0.62,0.85)	0.94	(0.59,1.42)	0.92	(0.83,1.02)	0.65	(0.02,3.62)	0.94	(0.57,1.47)
	BIMODO	1.02	(0.86,1.19)	1.07	(0.67,1.62)	0.91	(0.81,1.02)	0		0.98	(0.55,1.61)
6	BNT	4.45	(0.92,13.02)	40.46	(1.02,225.42)	4.37	(1.42,10.20)	108.71	(2.75,605.68)	113.98	(2.89,635.07)
	BIBNT	0.70	(0.41,1.12)	0.52	(0.14,1.32)	0.53	(0.40,0.69)	0		0	
	BIMODO	0.63	(0.29,1.20)	0.38	(0.05,1.38)	0.32	(0.20,0.48)	15.65	(0.40,87.17)	1.68	(0.46,4.31)
7	BIBNT	3.39	(0.41,12.23)	10.65	(1.29,38.46)	0.41	(0.01,2.29)	0		0	

AESI: THR= Thrombocytopenia, ITP= Idiopathic thrombocytopenia, PEM= Pulmonary embolism, CVST=Cerebral venous sinus thrombosis, SVT= Splanchnic vein thrombosis

Supplementary Table 13: All aggregated OE Ratios by last dose, cardiovascular conditions, period 0–42 days, PYRS≥1000, no censoring on observed counts

		MYO		PER	
Dose	Vaccine	OE_Ratio	CI	OE_Ratio	CI
1	AZD	1.36	(1.08,1.68)	1.29	(1.15,1.44)
	BNT	2.78	(2.61,2.95)	1.54	(1.47,1.62)
	MOD	3.48	(3.00,4.01)	1.74	(1.54,1.97)
	BIBNT	20.99	(0.53,116.94)	0	
	NVX	20.18	(0.51,112.44)	13.73	(2.83,40.12)
	PBNT	10.41	(4.18,21.44)	1.22	(0.03,6.82)
	BIBP	0		0	
	VGM	0		0	
	JJJ	1.64	(0.87,2.80)	0.81	(0.54,1.18)
	SINO	0		0	
	HMOD	0		0	
2	AZD	1.31	(1.01,1.68)	1.27	(1.12,1.43)
	BNT	2.86	(2.70,3.03)	1.38	(1.32,1.45)
	MOD	6.10	(5.52,6.72)	1.67	(1.50,1.85)
	BIBNT	0		0	
	NVX	39.26	(0.99,218.74)	33.99	(4.12,122.78)
	PBNT	8.98	(2.45,22.98)	4.54	(0.94,13.26)
	BIBP	0		0	
	VGM	0		0	
	SINO	0		0	
3	AZD	0		6.91	(3.45,12.36)
	BNT	2.09	(1.88,2.32)	1.19	(1.10,1.28)
	MOD	2.01	(1.60,2.49)	1.39	(1.20,1.59)
	BIBNT	0		1.21	(0.03,6.77)
	BIMODO	0		3.00	(0.36,10.85)
	NVX	0		9.72	(2.01,28.42)
	PBNT	0		12.42	(0.31,69.22)
	HMOD	1.80	(0.49,4.61)	0.64	(0.21,1.49)
4	AZD	66.79	(8.09,241.26)	53.41	(14.55,136.75)
	BNT	2.06	(1.47,2.80)	1.55	(1.30,1.83)
	MOD	2.91	(1.45,5.21)	2.64	(2.05,3.35)
	BIBNT	1.45	(0.47,3.37)	0.98	(0.56,1.59)
	BIMODO	2.28	(0.92,4.70)	1.63	(1.03,2.45)
	NVX	0		49.87	(6.04,180.15)
5	BNT	11.27	(0.29,62.82)	9.39	(4.29,17.82)
	MOD	25.83	(0.65,143.92)	4.14	(0.10,23.06)
	BIBNT	1.73	(0.56,4.04)	2.02	(1.45,2.75)
	BIMODO	2.31	(0.63,5.92)	1.85	(1.19,2.72)
6	BNT	0		41.43	(1.05,230.85)
	BIBNT	3.59	(0.09,20.02)	2.35	(0.86,5.11)
	BIMODO	0		0.61	(0.02,3.40)
7	BIBNT	0		0	

AESI: MYO= Myocarditis, PER= Pericarditis

Vaccine abbreviations:

Code	Vaccine brand
AZD	Covishield or Vaxzevria [AstraZeneca or Serum Institute of India]
BNT	Comirnaty or Tozinameran [Pfizer/BioNTech or Fosun-BioNTech]
MOD	Elasomeran or Spikevax or TAK-919 [Moderna or Takeda]
BIBNT	Comirnaty or Riltozinameran or Pfizer/BioNTech COVID-19 Vaccine Bivalent [Pfizer/BioNTech]
NVX	Covovax or Nuvaxoid [Novavax or Serum Institute of India]
PBNT	Comirnaty or Tozinameran Paediatric [Pfizer/BioNTech or Fosun-BioNTech]
BIBP	Covilo or SARS-CoV-2 Vaccine (Vero Cell) [Sinopharm (Beijing)]
VGM	Sputnik V [Gamaleya Research Institute]
JJJ	Janssen [Janssen/Johnson & Johnson]
SINO	CoronaVac or Sinovac [Sinovac Biotech]
HMOD	Elasomeran or Spikevax or TAK-919 Half Dose [Moderna or Takeda]
BIMODO	Spikevax bivalent Original/Omicron [Moderna]

Thresholds for statistical indications of potential signals:

Red: LBCI* >1.5, statistically significant safety signal

Yellow: LBCI* >1 and ≤1.5, statistically significant

Green: LBCI* ≤1.0, not statistically significant

*LBCI: Lower bound of confidence interval

Conditions applied to the analysis of aggregated OE ratios:

- PYRS ≥1000
- No censoring on observed counts